{"id":58660,"date":"2026-03-03T13:54:48","date_gmt":"2026-03-03T05:54:48","guid":{"rendered":"https:\/\/flcube.com\/?p=58660"},"modified":"2026-03-03T13:54:49","modified_gmt":"2026-03-03T05:54:49","slug":"lepu-medicals-sirna-mwx401-wins-nmpa-approval-rnai-therapy-targets-primary-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58660","title":{"rendered":"Lepu Medical&#8217;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension"},"content":{"rendered":"\n<p><strong>Lepu Medical Technology (<a href=\"https:\/\/www.google.com\/finance\/quote\/300003:SHE\">SHE:\u202f300003<\/a>)<\/strong>, a <strong>cardiovascular disease solutions provider<\/strong>, announced <strong>clinical approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>MWX401<\/strong>, a <strong>small interfering RNA (siRNA)<\/strong> drug targeting <strong>primary hypertension<\/strong>. The approval enables <strong>Phase I\/II clinical trials<\/strong> for the <strong>RNAi therapeutic<\/strong>, supported by <strong>strong preclinical data<\/strong> demonstrating <strong>sustained blood pressure reduction<\/strong> and <strong>superior efficacy vs. standard\u2011of\u2011care<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Lepu Medical Technology (SHE:\u202f300003)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>MWX401<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small interfering RNA (siRNA)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Primary hypertension<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>AGT (angiotensinogen)<\/strong> \u2013 key regulator of blood pressure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Model<\/th><th>MWX401 Result<\/th><th>Comparator<\/th><\/tr><\/thead><tbody><tr><td><strong>Humanized Hypertensive Mice<\/strong><\/td><td>Significant reduction in: serum target protein, mRNA, systolic BP, diastolic BP<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Spontaneously Hypertensive Rhesus Monkeys<\/strong><\/td><td>Marked AGT level reduction; significant BP lowering<\/td><td><strong>Superior to valsartan<\/strong><\/td><\/tr><tr><td><strong>Dose\u2011Response<\/strong><\/td><td>Good dose\u2011response relationship<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Duration of Effect<\/strong><\/td><td><strong>\u2265\u202f12 weeks<\/strong> sustained BP reduction<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Good safety demonstrated<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RNAi Cardiovascular Entry:<\/strong> MWX401 represents <strong>Lepu Medical&#8217;s expansion from devices (stents, valves) into RNA therapeutics<\/strong>, diversifying beyond interventional cardiology into <strong>pharmaceutical innovation<\/strong>.<\/li>\n\n\n\n<li><strong>AGT Target Validation:<\/strong> Targeting <strong>angiotensinogen (AGT)<\/strong>\u2014the <strong>upstream precursor<\/strong> of angiotensin II\u2014offers <strong>complete pathway suppression<\/strong> vs. ACE inhibitors or ARBs, potentially providing <strong>superior, longer\u2011lasting BP control<\/strong>.<\/li>\n\n\n\n<li><strong>Sustained Efficacy Advantage:<\/strong> <strong>12\u2011week duration<\/strong> from single subcutaneous dose suggests <strong>quarterly or less frequent dosing<\/strong>, dramatically improving <strong>patient compliance<\/strong> vs. daily oral antihypertensives.<\/li>\n\n\n\n<li><strong>Non\u2011Clinical Superiority:<\/strong> <strong>Superior to valsartan<\/strong>\u2014a gold\u2011standard ARB\u2014supports <strong>best\u2011in\u2011class potential<\/strong> and <strong>premium positioning<\/strong> in the <strong>$30\u202fbillion+ global hypertension market<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Hypertension Market<\/strong><\/td><td>~\u202f$30\u202fbillion globally; dominated by generic ACE inhibitors, ARBs, and calcium channel blockers; innovation gap for resistant hypertension<\/td><\/tr><tr><td><strong>RNAi vs. Small Molecule<\/strong><\/td><td>siRNA offers <strong>durable, specific gene silencing<\/strong> with quarterly dosing; addresses adherence crisis in chronic cardiovascular disease management<\/td><\/tr><tr><td><strong>AGT Competition<\/strong><\/td><td>Alnylam&#8217;s zilebesiran (AGT siRNA) in Phase III; MWX401 positions Lepu as <strong>domestic China competitor<\/strong> with potential for <strong>differentiated profile<\/strong><\/td><\/tr><tr><td><strong>Lepu Medical Diversification<\/strong><\/td><td>siRNA platform expands beyond device\u2011centric model; supports <strong>higher valuation multiples<\/strong> and <strong>partnership attractiveness<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I\/II enrollment, AGT target engagement confirmation, and sustained BP reduction in humans. Actual results may differ due to risks including immunogenicity, off\u2011target effects, and competitive zilebesiran development timeline.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8eMWX401\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8eMWX401\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-bc1ff4b8-f917-41ee-ac7a-6c1901969da9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8eMWX401\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8eMWX401\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u4e50\u666e\u533b\u7597\uff1a\u5173\u4e8eMWX401\u6ce8\u5c04\u6db2\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bc1ff4b8-f917-41ee-ac7a-6c1901969da9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,108,374,64,864],"class_list":["post-58660","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-high-blood-pressure","tag-lepu-medical-technology","tag-rnai-aso","tag-she-300003"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu Medical&#039;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China&#039;s National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58660\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical&#039;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension\" \/>\n<meta property=\"og:description\" content=\"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China&#039;s National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58660\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T05:54:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T05:54:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical&#8217;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension\",\"datePublished\":\"2026-03-03T05:54:48+00:00\",\"dateModified\":\"2026-03-03T05:54:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"High blood pressure\",\"Lepu Medical Technology\",\"RNAi \\\/ ASO\",\"SHE: 300003\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58660#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58660\",\"name\":\"Lepu Medical's siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T05:54:48+00:00\",\"dateModified\":\"2026-03-03T05:54:49+00:00\",\"description\":\"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China's National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\\\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58660\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58660#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical&#8217;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical's siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China's National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58660","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical's siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension","og_description":"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China's National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.","og_url":"https:\/\/flcube.com\/?p=58660","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T05:54:48+00:00","article_modified_time":"2026-03-03T05:54:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58660#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58660"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical&#8217;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension","datePublished":"2026-03-03T05:54:48+00:00","dateModified":"2026-03-03T05:54:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58660"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","High blood pressure","Lepu Medical Technology","RNAi \/ ASO","SHE: 300003"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58660#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58660","url":"https:\/\/flcube.com\/?p=58660","name":"Lepu Medical's siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T05:54:48+00:00","dateModified":"2026-03-03T05:54:49+00:00","description":"Lepu Medical Technology (SHE:\u202f300003), a cardiovascular disease solutions provider, announced clinical approval from China's National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I\/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard\u2011of\u2011care.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58660#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58660"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58660#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical&#8217;s siRNA MWX401 Wins NMPA Approval \u2013 RNAi Therapy Targets Primary Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58660"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58660\/revisions"}],"predecessor-version":[{"id":58662,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58660\/revisions\/58662"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}